{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Biogen Inc."},"Symbol":{"label":"Symbol","value":"BIIB"},"Address":{"label":"Address","value":"225 BINNEY STREET, CAMBRIDGE, Massachusetts, 02142, United States"},"Phone":{"label":"Phone","value":"+1 617 679-2000"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021."},"CompanyUrl":{"label":"Company Url","value":"https://www.biogen.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Christopher A. Viehbacher","title":"President, Chief Executive Officer & Director"},{"name":"Daniel Quirk","title":"Chief Medical Officer & Head-Medical Affairs"},{"name":"Jane Grogan","title":"Executive Vice President & Head-Research"},{"name":"Nicole Murphy","title":"Head-Pharmaceutical Operations & Technology"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}